A5032721048- Blood groups and transfusion
- Platelet Disorders and Treatments
- Extracellular vesicles in disease
- Erythrocyte Function and Pathophysiology
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Diabetes and associated disorders
- Cell Adhesion Molecules Research
- Inflammatory Biomarkers in Disease Prognosis
- Blood transfusion and management
- Hepatitis B Virus Studies
- Complement system in diseases
- Hematopoietic Stem Cell Transplantation
- Immunotherapy and Immune Responses
- Adenosine and Purinergic Signaling
- Antiplatelet Therapy and Cardiovascular Diseases
- Immune Response and Inflammation
- Renal Transplantation Outcomes and Treatments
- HIV-related health complications and treatments
- Proteoglycans and glycosaminoglycans research
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Immune cells in cancer
- Mesenchymal stem cell research
- Venous Thromboembolism Diagnosis and Management
Inserm
2013-2025
Institut Mondor de Recherche Biomédicale
2013-2025
Université Paris-Est Créteil
2020-2025
Établissement Français du Sang
2015-2025
Biologie Intégrée du Globule Rouge
2017-2025
Institut des Maladies Génétiques Imagine
2024
Laboratory of Excellence GR-Ex
2015-2023
Hôpitaux Universitaires Henri-Mondor
2013
Generation of de novo donor-specific antibodies ( dn DSAs) after renal transplant is recognized as the leading cause late failure. Hence, optimal immunosuppressive strategies to limit DSA development need be defined. Recent clinical trials using novel costimulatory blockade agent CTLA4-Ig (Belatacept) have shown that kidney recipients (KTRs) treated with Belatacept better graft survival and function a lower proportion DSAs than control-treated KTRs. Mechanisms involved in control humoral...
Introduction The immunological profiles of CD4 + T lymphocytes (TLs) from patients with hematological malignancies differ between who have and not received transfusions. There may be several reasons for these differences, including the presence extracellular vesicles (EVs) derived plasma membrane budding present in platelet concentrates. Indeed, EVs can modulate immune system through interactions many cells, but underlying mechanisms remain incompletely understood. Methods We therefore...
Alloimmunization against red blood cells (RBCs) is the main immunological risk associated with transfusion in patients sickle cell disease (SCD). However, about 50-70% of SCD never get immunized despite frequent transfusion. In murine models, CD4(+) T play a key role RBC alloimmunization. We therefore explored and compared T-cell phenotypes functions between group (n = 11) who became high regimen 10) had become (at least Kidd antigen b) after low regimen. studied markers function, including...
Introduction People living with HIV (PLWH) now benefit from combined antiviral treatments that durably control viral replication. These antiretroviral decrease mortality and improve quality of life in PLWH, but do not completely the excessive non-specific activation immune system PLWH. This chronic is a key element immunopathology contributes to pathophysiology inflammatory comorbid conditions, such as cardiovascular disorders, cancer autoimmune diseases. Circulating non-exosomal...
Introduction CD39 plays an important role in the immunoregulation and inhibition of effector cells. It is expressed on immune cells, including Tregs, extracellular vesicles (EVs) budding from plasma membrane. Platelet transfusion may induce alloimmunization against HLA-I antigens, leading to refractoriness platelet with severe consequences for patients. Tregs play a key determining whether occurs patients hematologic disorders. We hypothesized that + EVs might immunoregulatory role,...
Introduction The treatment of chronic viral infections can often bring replication under control. However, immune activation persists and lead to the development comorbid conditions, such as cardiovascular disease cancer. This is particularly true for people living with HIV (PLWH), who have significantly more extracellular vesicles from membrane budding, also called plasma microparticles (MPs), than healthy individuals (HDs), a much immunomodulatory phenotype. We hypothesized that number...
Sickle cell disease (SCD) is a chronic inflammatory associated with multiple organ damage, anemia, and infections. SCD patients have high rate of alloimmunization against red blood cells (RBCs) following transfusion may develop autoimmune diseases. Studies in mouse models suggested that regulatory T (Treg) play role RBC antigens. We characterized the phenotype function Treg population homogeneous cohort transfused patients. found distribution subpopulations differed significantly between...
Murine models of red blood cell transfusion show that inflammation associated with viruses or methylated DNA promotes alloimmunization. In vaccination studies, the intensity antigen-specific responses depends on delay between antigen and adjuvant administration, a short limiting immune responses. mouse alloimmunization, injection Toll-like receptor agonists is usually short. this study, we hypothesized timing 3 agonist administration affects Poly(I:C), agonist, was administered to B10BR mice...
Introduction Aplasia and hematological malignancies are treated with platelet transfusions, which can have major immunomodulatory effects. Platelet concentrates (PCs) contain many elements, including the platelets themselves, residual leukocytes, extracellular vesicles, such as microparticles (MPs), cytokines other soluble elements. Two of these components, MPs a form CD27 (sCD27), been shown to play particularly important role in immune system modulation. The loss expression is an...
Abstract It is essential to limit hemolytic transfusion reactions in polytransfused individuals, and the prevention of alloimmunization a key solution. CD4+ T lymphocyte (TL) markers, particularly follicular helper (Tfh) cells, may differentiate between responder nonresponder statuses. We tested this hypothesis by studying phenotype CXCR5+PD1+ TLs whole blood. Our results suggest that high levels CXCR5+PD1+CD4+ blood be characteristic nonalloimmunized patients. However, these cells did not...
Extracellular vesicles (EVs), which are generated by cell membrane budding in diverse cells, present variable numbers the blood. An immunoregulatory role has been demonstrated principally for heterologous EVs, but function of EVs naturally blood remains unknown. We hypothesize that these autologous might also modulate phenotype and immune system especially CD4 + T lymphocytes (TLs), as previously described EVs. Several membranes soluble molecules were studied after treatment TLs with No...
Abstract Alloimmunization against RBCs can cause life-threatening delayed hemolytic transfusion reactions. Anti-CD20 Ab has recently been used to prevent alloimmunization. However, its effects remain unclear, particularly in lymphoid organs. We investigated the impact of murine anti-CD20 blood and spleen. assessed protocols for preventing primary alloimmunization abolishing established Prophylactic prevented treatment could only limit further amplification Residual B cell subtype...
Acute myeloid leukemia (AML) is one of the commonest hematologic disorders. Due to high frequency disease- or treatment-related thrombocytopenia, AML requires treatment with multiple platelet transfusions, which can trigger a humoral response directed against platelets. Some, but not all, patients develop an anti-HLA immune after transfusions. We therefore hypothesized that different activation profiles might be associated alloimmunization status.We tested this hypothesis, by analyzing CD4+...
Abstract Background Platelet (PLT) transfusions are an essential treatment for bleeding disorders. However, immunologic complications can occur, including alloantibody production against Class I HLA molecules. The principal source of molecules in PLT concentrates (PCs) is the PLTs themselves. extracellular microparticles (MPs) present PCs may express Study Design and Methods We used nanoscale flow cytometry to explore expression HLA‐A2, HLA‐B7, HLA‐B57 on surface cells, PLT‐derived MPs...
à la diffusion de documents scientifiques niveau recherche, publiés ou non, émanant des établissements d'enseignement et recherche français étrangers, laboratoires publics privés.
Abstract Background Patients with hematologic malignancies require prophylactic or curative platelet transfusions to prevent treat bleeding. Treatments such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation cause persistent thrombocytopenia, necessitating transfusions. However, class I HLA antibodies can a serious complication: immune‐mediated refractoriness. The mechanisms of alloimmunization are incompletely understood. We explored the immunogenicity molecules...